What are your top takeaways in Head & Neck Cancers from ASCO 2024?  

The PATHWay study Abstract 6008: checkpoint inhibitor therapy has become instrumental in the treatment of recurrent and metastatic head and neck squamous cell carcinomas. However, we still do not have data to inform us whether treatment with such agents is beneficial in the adjuvant setting. In th...

There were many interesting abstracts in the Head and Neck section presented at ASCO this year. In addition to the abstracts presented on EBV and HPV-mediated cancers, the following three abstracts stood out to me in terms of novelty, drug development, and high unmet need. The PATHWay study, Abst...

I would like to highlight the DIPPER study: Adjuvant PD-1 blockade with Camrelizumab in high-risk locoregionally advanced NPC- A multicenter, open-label, phase 3, randomized controlled trial by Ma et al.:  Adjuvant PD-1 inhibition significantly improved PFS in patients with NPC who receiv...